RHEBL1

Summary

RHEBL1 (RHEB like 1, HGNC:21166) is a protein-coding gene on chromosome 12q13.12, encoding GTPase RhebL1 (Q8TAI7). Binds GTP and exhibits intrinsic GTPase activity.

Enables GTP binding activity. Involved in TOR signaling and positive regulation of NF-kappaB transcription factor activity. Located in cytoplasm.

Source: NCBI Gene 121268 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 24 total
• MANE Select transcript: NM_144593

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21166
Approved symbol	RHEBL1
Name	RHEB like 1
Location	12q13.12
Locus type	gene with protein product
Status	Approved
Aliases	MGC34869, FLJ25797, RHEB2
Ensembl gene	ENSG00000167550
Ensembl biotype	protein_coding
OMIM	618956
Entrez	121268

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 5 protein_coding, 2 nonsense_mediated_decay

ENST00000301068, ENST00000420065, ENST00000550675, ENST00000550797, ENST00000918572, ENST00000918573, ENST00000918574

RefSeq mRNA: 2 — MANE Select: NM_144593 NM_001303126, NM_144593

CCDS: CCDS8778

Canonical transcript exons

ENST00000301068 — 8 exons

Exon	Start	End
ENSE00001114192	49069035	49069106
ENSE00001276258	49064676	49065192
ENSE00003490170	49066619	49066701
ENSE00003560744	49066968	49067035
ENSE00003566967	49066231	49066278
ENSE00003606072	49065350	49065431
ENSE00003654226	49066476	49066532
ENSE00003850630	49069734	49069979

Expression profiles

Bgee: expression breadth ubiquitous, 175 present calls, max score 93.28.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7001 / max 34.2610, expressed in 293 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
130798	0.6360	276
130795	0.0641	19

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	93.28	gold quality
secondary oocyte	CL:0000655	92.41	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.70	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.08	gold quality
middle temporal gyrus	UBERON:0002771	83.31	gold quality
endothelial cell	CL:0000115	82.40	gold quality
Brodmann (1909) area 23	UBERON:0013554	81.24	gold quality
right uterine tube	UBERON:0001302	80.61	gold quality
granulocyte	CL:0000094	80.20	gold quality
prefrontal cortex	UBERON:0000451	79.51	gold quality
Brodmann (1909) area 9	UBERON:0013540	78.00	gold quality
right frontal lobe	UBERON:0002810	77.73	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	76.79	gold quality
frontal cortex	UBERON:0001870	76.68	gold quality
neocortex	UBERON:0001950	75.74	gold quality
anterior cingulate cortex	UBERON:0009835	75.06	gold quality
primary visual cortex	UBERON:0002436	75.05	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	73.52	gold quality
cerebral cortex	UBERON:0000956	72.97	gold quality
bronchial epithelial cell	CL:0002328	72.89	gold quality
tibial nerve	UBERON:0001323	72.76	gold quality
bronchus	UBERON:0002185	72.33	gold quality
occipital lobe	UBERON:0002021	72.14	gold quality
stromal cell of endometrium	CL:0002255	71.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	71.90	gold quality
cerebellar hemisphere	UBERON:0002245	71.48	gold quality
cerebellar cortex	UBERON:0002129	71.37	gold quality
spleen	UBERON:0002106	71.22	gold quality
lymph node	UBERON:0000029	70.97	gold quality
ventricular zone	UBERON:0003053	70.82	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.66

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

22 targeting RHEBL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-365A-3P	99.43	70.02	836
HSA-MIR-365B-3P	99.43	70.02	836
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-154-5P	98.92	66.65	733
HSA-MIR-138-2-3P	98.91	68.33	1643
HSA-MIR-648	98.64	66.13	553
HSA-MIR-6879-3P	93.93	64.00	759

Literature-anchored findings (GeneRIF, showing 7)

• Data show that Rheb like-1 protein (RhebL1) rescues mTOR signaling during nutrient withdrawal, and identify critical residues in Rheb and RhebL1 which are required for their efficient activation of mTOR signaling. (PMID:16098514)
• RHEBL1 is a positive regulator of NF-kappa B-mediated gene transcription. (PMID:16328882)
• RhebL1 may be impacting the mTOR pathway in a different manner than Rheb1. (PMID:21655954)
• Findings are unprecedented and indicate that the DHH-RHEBL1 fusion transcript is a novel recurrent feature in the changing landscape of CBFA2T3-GLIS2-positive childhood AML. (PMID:24127550)
• These results establish CAD as a downstream effector of Rheb and suggest a possible role of Rheb in regulating de novo pyrimidine nucleotide synthesis.(Rheb small GTPases, which consist of Rheb1 and Rheb2 (also known as RhebL1) (PMID:25422319)
• High RHEBL1 expression is associated with lung cancer. (PMID:28209923)
• Rheb1 promotes glucose-stimulated insulin secretion in human and mouse beta-cells by upregulating GLUT expression. (PMID:34375645)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rhebl1	ENSMUSG00000023755
rattus_norvegicus	Rhebl1	ENSRNOG00000054385

Paralogs (35): RALA (ENSG00000006451), REM1 (ENSG00000088320), RASL10A (ENSG00000100276), RASD2 (ENSG00000100302), RASL12 (ENSG00000103710), RHEB (ENSG00000106615), RASD1 (ENSG00000108551), RERGL (ENSG00000111404), RAP1A (ENSG00000116473), RASL11A (ENSG00000122035), RAP2C (ENSG00000123728), RAP2A (ENSG00000125249), RRAS (ENSG00000126458), RAP1B (ENSG00000127314), RASL11B (ENSG00000128045), KRAS (ENSG00000133703), RRAS2 (ENSG00000133818), RERG (ENSG00000134533), REM2 (ENSG00000139890), RIT1 (ENSG00000143622), RALB (ENSG00000144118), RIT2 (ENSG00000152214), MRAS (ENSG00000158186), DIRAS3 (ENSG00000162595), GEM (ENSG00000164949), DIRAS2 (ENSG00000165023), RRAD (ENSG00000166592), NKIRAS2 (ENSG00000168256), HRAS (ENSG00000174775), DIRAS1 (ENSG00000176490), RAP2B (ENSG00000181467), ERAS (ENSG00000187682), NKIRAS1 (ENSG00000197885), NRAS (ENSG00000213281), RASL10B (ENSG00000270885)

Protein

Protein identifiers

GTPase RhebL1 — Q8TAI7 (reviewed: Q8TAI7)

Alternative names: Ras homolog enriched in brain like-1 c, Ras homolog enriched in brain-like protein 1, Rheb2

All UniProt accessions (3): C9JQQ1, Q8TAI7, F8W1T5

UniProt curated annotations — full annotation on UniProt →

Function. Binds GTP and exhibits intrinsic GTPase activity. May activate NF-kappa-B-mediated gene transcription. Promotes signal transduction through MTOR, activates RPS6KB1, and is a downstream target of the small GTPase-activating proteins TSC1 and TSC2.

Subunit / interactions. Interacts with MTOR.

Subcellular location. Endomembrane system. Cytoplasm.

Tissue specificity. Ubiquitously expressed. Expression increased at least 2-fold in several tumor cell lines.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Similarity. Belongs to the small GTPase superfamily. Rheb family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TAI7-1	1	yes
Q8TAI7-2	2

RefSeq proteins (2): NP_001290055, NP_653194* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR020849	Small_GTPase_Ras-type	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00071

Enzyme classification (BRENDA):

• EC 3.6.5.2 — small monomeric GTPase (BRENDA: 49 organisms, 138 substrates, 55 inhibitors, 5 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GTP	—	0

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (31 total): strand 6, helix 6, binding site 6, mutagenesis site 5, splice variant 2, chain 1, propeptide 1, lipid moiety-binding region 1, short sequence motif 1, turn 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3OES	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TAI7-F1	92.71	0.83

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 16–21; 32–38; 38; 63; 119–122; 149–150

Post-translational modifications (2): 180, 180

Mutagenesis-validated functional residues (5):

Position	Phenotype
41	partially impaired in rps6k1 activation.
54	partially deficient in guanine nucleotide binding.
56	partially deficient in guanine nucleotide binding.
60	significant decrease in nf-kappa b activation.
64	constitutively active.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 143 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_POSITIVE_REGULATION_OF_TOR_SIGNALING, GGGTGGRR_PAX4_03, USF_C, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, GOMF_KINASE_ACTIVATOR_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, MYCMAX_01, BRN2_01, ARGGGTTAA_UNKNOWN, GOBP_POSITIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_POSITIVE_REGULATION_OF_DNA_BINDING_TRANSCRIPTION_FACTOR_ACTIVITY, RYTTCCTG_ETS2_B, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOBP_TOR_SIGNALING

GO Biological Process (4): small GTPase-mediated signal transduction (GO:0007264), TOR signaling (GO:0031929), obsolete positive regulation of NF-kappaB transcription factor activity (GO:0051092), signal transduction (GO:0007165)

GO Molecular Function (7): GTPase activity (GO:0003924), GTP binding (GO:0005525), GDP binding (GO:0019003), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (4): cytoplasm (GO:0005737), plasma membrane (GO:0005886), endomembrane system (GO:0012505), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
guanyl ribonucleotide binding	2
intracellular signaling cassette	1
intracellular signal transduction	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
ribonucleoside triphosphate phosphatase activity	1
purine ribonucleoside triphosphate binding	1
anion binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

1588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RHEBL1	RRAGB	Q5VZM2	673
RHEBL1	TSC2	P49815	555
RHEBL1	TBC1D7	Q9P0N9	505
RHEBL1	TSC1	Q92574	497
RHEBL1	RPTOR	Q8N122	471
RHEBL1	MTOR	P42345	460
RHEBL1	PDE6D	O43924	459
RHEBL1	PSMG1	O95456	427
RHEBL1	LAMP2	P13473	423
RHEBL1	RRAGC	Q9HB90	418
RHEBL1	MLST8	Q9BVC4	414
RHEBL1	RRAGA	Q7L523	411
RHEBL1	LAMP1	P11279	396
RHEBL1	SLC45A3	Q96JT2	396
RHEBL1	ELK4	P28323	387

IntAct

30 interactions, top by confidence:

A	B	Type	Score
PRKAB2	RHEBL1	psi-mi:“MI:0915”(physical association)	0.780
RHEBL1	PRKAB2	psi-mi:“MI:0915”(physical association)	0.780
RHEBL1	FHL3	psi-mi:“MI:0915”(physical association)	0.560
APPL1	RHEBL1	psi-mi:“MI:0915”(physical association)	0.560
RHEBL1	APPL1	psi-mi:“MI:0915”(physical association)	0.560
FHL3	RHEBL1	psi-mi:“MI:0915”(physical association)	0.560
UCHL1	RHEBL1	psi-mi:“MI:0915”(physical association)	0.560
RHEBL1	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
ATXN1	RHEBL1	psi-mi:“MI:0915”(physical association)	0.560
RHEBL1	TXNL4A	psi-mi:“MI:0915”(physical association)	0.550
TXNL4A	RHEBL1	psi-mi:“MI:0915”(physical association)	0.550
TRAF2	RHEBL1	psi-mi:“MI:0915”(physical association)	0.400
RHEBL1	MTOR	psi-mi:“MI:0915”(physical association)	0.400
RHEBL1	Appl1	psi-mi:“MI:0915”(physical association)	0.370
RHEBL1	Blzf1	psi-mi:“MI:0915”(physical association)	0.370
RHEBL1	Traf2	psi-mi:“MI:0915”(physical association)	0.370
PRKAB2	RHEBL1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (14): RHEBL1 (Affinity Capture-Western), RHEBL1 (Two-hybrid), RHEBL1 (Two-hybrid), RHEBL1 (Two-hybrid), RHEBL1 (Two-hybrid), FHL3 (Two-hybrid), RHEBL1 (Two-hybrid), RHEBL1 (Affinity Capture-RNA), TRAF2 (Affinity Capture-Western), Appl1 (Two-hybrid), Blzf1 (Two-hybrid), Traf2 (Two-hybrid), TXNL4A (Two-hybrid), RHEBL1 (Two-hybrid)

ESM2 similar proteins: A1DZY4, A6QP66, O35626, P0C0E4, P51157, P51158, P55040, P55041, P57729, P63032, P63033, P70425, Q06AU5, Q0VCJ7, Q12829, Q13637, Q19143, Q3SWY9, Q5BJQ5, Q5E9J3, Q5FVY2, Q5R541, Q5RFI2, Q6DGN0, Q6IMA3, Q6IMA7, Q6IMB1, Q6P0U3, Q6T310, Q7TNZ5, Q7YS69, Q8AVS6, Q8QZZ8, Q8R367, Q8TAI7, Q8VHP8, Q8VHQ4, Q8WXH6, Q922H7, Q92730

Diamond homologs: A1DZY4, A6QP66, A8NU18, C4YKT4, O08989, O14807, O35929, O88667, O93856, O94363, P01119, P03967, P08645, P08647, P0CY32, P10114, P10536, P11233, P11234, P15064, P17609, P22124, P22126, P22278, P22279, P22280, P28775, P32254, P36860, P36863, P48555, P59279, P61105, P61225, P61226, P61227, P62070, P62071, P63320, P63321

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

24 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	12
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1229 predictions. Top by Δscore:

Variant	Effect	Δscore
12:49065188:GTCAG:G	acceptor_gain	1.0000
12:49065189:TCAG:T	acceptor_gain	1.0000
12:49065190:CAG:C	acceptor_gain	1.0000
12:49065190:CAGC:C	acceptor_gain	1.0000
12:49065191:AG:A	acceptor_gain	1.0000
12:49065192:GCTA:G	acceptor_loss	1.0000
12:49065193:C:CC	acceptor_gain	1.0000
12:49065195:A:C	acceptor_gain	1.0000
12:49065325:C:A	donor_gain	1.0000
12:49069027:CTACT:C	donor_loss	1.0000
12:49069029:ACT:A	donor_loss	1.0000
12:49069030:C:CA	donor_loss	1.0000
12:49069031:TCA:T	donor_loss	1.0000
12:49069032:CA:C	donor_loss	1.0000
12:49069033:A:AC	donor_gain	1.0000
12:49069033:A:T	donor_loss	1.0000
12:49069034:C:CA	donor_gain	1.0000
12:49069034:CT:C	donor_gain	1.0000
12:49069034:CTA:C	donor_gain	1.0000
12:49069034:CTAT:C	donor_gain	1.0000
12:49069034:CTATT:C	donor_gain	1.0000
12:49069183:C:CT	acceptor_gain	1.0000
12:49069183:C:T	acceptor_gain	1.0000
12:49065195:A:AC	acceptor_gain	0.9900
12:49065321:ACCAC:A	donor_gain	0.9900
12:49065322:CCACC:C	donor_gain	0.9900
12:49065451:A:C	acceptor_gain	0.9900
12:49066276:ACCCT:A	acceptor_loss	0.9900
12:49066277:CC:C	acceptor_gain	0.9900
12:49066277:CCCTG:C	acceptor_loss	0.9900

AlphaMissense

1183 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:49066532:G:C	S92R	0.992
12:49066532:G:T	S92R	0.992
12:49066620:T:G	S92R	0.992
12:49069100:G:A	T20I	0.991
12:49069066:G:C	F31L	0.990
12:49069066:G:T	F31L	0.990
12:49069068:A:G	F31L	0.990
12:49069104:T:G	K19Q	0.990
12:49066251:C:A	K120N	0.989
12:49066251:C:G	K120N	0.989
12:49069748:C:T	G13E	0.988
12:49069749:C:G	G13R	0.988
12:49069749:C:T	G13R	0.988
12:49066638:A:G	S86P	0.987
12:49066655:C:T	G80D	0.987
12:49069102:C:A	K19N	0.987
12:49069102:C:G	K19N	0.987
12:49066267:A:T	V115D	0.986
12:49069734:C:G	G18R	0.985
12:49069734:C:T	G18R	0.985
12:49066987:A:G	L58P	0.983
12:49069103:T:A	K19M	0.982
12:49069734:C:A	G18W	0.982
12:49066982:C:G	D60H	0.981
12:49066993:A:G	L56P	0.980
12:49066998:A:C	F54L	0.980
12:49066998:A:T	F54L	0.980
12:49067000:A:G	F54L	0.980
12:49069106:C:T	G18E	0.980
12:49065377:A:C	F145L	0.979

dbSNP variants (sampled 300 via entrez): RS1000129717 (12:49070914 C>T), RS1000172834 (12:49067378 C>T), RS1000836120 (12:49067652 T>C), RS1000897758 (12:49065175 G>A), RS1001116367 (12:49070314 G>C), RS1001240129 (12:49065605 A>G), RS1001440527 (12:49069314 G>A,C,T), RS1002069365 (12:49064668 A>G,T), RS1002120346 (12:49071862 C>T), RS1002187219 (12:49070388 T>C), RS1002441387 (12:49065020 G>A,C), RS1002797906 (12:49068976 G>A), RS1002977565 (12:49065523 C>T), RS1004087444 (12:49068113 C>A), RS1004375966 (12:49070307 C>G,T)

Disease associations

OMIM: gene MIM:618956 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004139_23	Bipolar disorder	6.000000e-08
GCST006268_245	Reaction time	9.000000e-09
GCST008103_109	Bipolar disorder	4.000000e-06
GCST011102_16	Bipolar disorder	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008393	reaction time measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	3
Arsenic	affects expression, affects methylation, decreases expression, increases abundance	3
Valproic Acid	affects expression, increases expression	3
trichostatin A	affects expression, increases expression	2
Acetaminophen	increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Particulate Matter	increases abundance, increases expression	2
GSK-J4	increases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	increases expression	1
sulforaphane	increases expression	1
butyraldehyde	increases expression	1
nickel sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	increases expression	1
NSC668394	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Amiodarone	increases expression	1
Cadmium	decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Estradiol	increases expression, affects cotreatment	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Methyl Methanesulfonate	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.